Competition Fails To Rein In Cancer Drug Prices
Executive Summary
A new analysis published in the public policy journal Health Affairs turns the attention of high drug prices, which lately has focused on hepatitis C medicines or companies like Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals Inc., back on oncology therapies – pointing out that competition in that space has done little to bring down the costs of those medications.